IBDEI0KB ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1009,0)
 ;;=EATING DISORDERS^10^106
 ;;^UTILITY(U,$J,358.4,1010,0)
 ;;=NEUROLEPTIC-INDUCED MOVEMENT DISORD^12^106
 ;;^UTILITY(U,$J,358.4,1011,0)
 ;;=CONTACT W/ HAZARDOUS SUBSTANCES^1^106
 ;;^UTILITY(U,$J,358.4,1012,0)
 ;;=BRAIN DISORDERS^6^106
 ;;^UTILITY(U,$J,358.4,1013,0)
 ;;=GROUP PSYCHOTHERAPY/INTERVENTION^2^107
 ;;^UTILITY(U,$J,358.4,1014,0)
 ;;=OTHER^5^107
 ;;^UTILITY(U,$J,358.4,1015,0)
 ;;=TEAM CONFERENCE^4^107
 ;;^UTILITY(U,$J,358.4,1016,0)
 ;;=SUBSTANCE ABUSE^3^107
 ;;^UTILITY(U,$J,358.4,1017,0)
 ;;=CASE MANAGEMENT^1^107
 ;;^UTILITY(U,$J,358.4,1018,0)
 ;;=ADJUSTMENT DISORDERS^2^108
 ;;^UTILITY(U,$J,358.4,1019,0)
 ;;=ANXIETY DISORDERS^4^108
 ;;^UTILITY(U,$J,358.4,1020,0)
 ;;=AMNESTICS^3^108
 ;;^UTILITY(U,$J,358.4,1021,0)
 ;;=ORGANIC DISORDERS^13^108
 ;;^UTILITY(U,$J,358.4,1022,0)
 ;;=DEMENTIA^8^108
 ;;^UTILITY(U,$J,358.4,1023,0)
 ;;=DELIRIUM^7^108
 ;;^UTILITY(U,$J,358.4,1024,0)
 ;;=BIPOLAR DISORDERS^5^108
 ;;^UTILITY(U,$J,358.4,1025,0)
 ;;=PSYCHOSIS/OTHER^17^108
 ;;^UTILITY(U,$J,358.4,1026,0)
 ;;=PERSONALITY DISORDERS^15^108
 ;;^UTILITY(U,$J,358.4,1027,0)
 ;;=SEXUAL DISORDERS^19^108
 ;;^UTILITY(U,$J,358.4,1028,0)
 ;;=SLEEP DISORDERS^20^108
 ;;^UTILITY(U,$J,358.4,1029,0)
 ;;=OTHER DISORDERS^14^108
 ;;^UTILITY(U,$J,358.4,1030,0)
 ;;=SUBSTANCE RELATED DISORDERS^22^108
 ;;^UTILITY(U,$J,358.4,1031,0)
 ;;=V CODES^23^108
 ;;^UTILITY(U,$J,358.4,1032,0)
 ;;=PREVENTION/COUNSELING/SCREEN^16^108
 ;;^UTILITY(U,$J,358.4,1033,0)
 ;;=DEPRESSION^9^108
 ;;^UTILITY(U,$J,358.4,1034,0)
 ;;=MOOD DISORDERS (OTHER)^11^108
 ;;^UTILITY(U,$J,358.4,1035,0)
 ;;=SCHIZOPHRENIA^18^108
 ;;^UTILITY(U,$J,358.4,1036,0)
 ;;=SOMATIFORM DISORDERS^21^108
 ;;^UTILITY(U,$J,358.4,1037,0)
 ;;=EATING DISORDERS^10^108
 ;;^UTILITY(U,$J,358.4,1038,0)
 ;;=NEUROLEPTIC-INDUCED MOVEMENT DISORD^12^108
 ;;^UTILITY(U,$J,358.4,1039,0)
 ;;=CONTACT W/ HAZARDOUS SUBSTANCES^1^108
 ;;^UTILITY(U,$J,358.4,1040,0)
 ;;=BRAIN DISORDERS^6^108
 ;;^UTILITY(U,$J,358.4,1041,0)
 ;;=EDUCATION^2^109
 ;;^UTILITY(U,$J,358.4,1042,0)
 ;;=MEDICAL NUTRITION THERAPY^3^109
 ;;^UTILITY(U,$J,358.4,1043,0)
 ;;=TEAM CONFERENCE^6^109
 ;;^UTILITY(U,$J,358.4,1044,0)
 ;;=ASSESSMENT^1^109
 ;;^UTILITY(U,$J,358.4,1045,0)
 ;;=MEDICATION THERAPY MANAGEMENT^4^109
 ;;^UTILITY(U,$J,358.4,1046,0)
 ;;=PHYSICAL THERAPY^5^109
 ;;^UTILITY(U,$J,358.4,1047,0)
 ;;=COUNSELING^2^110
 ;;^UTILITY(U,$J,358.4,1048,0)
 ;;=DIABETES W/O COMPLICATION^3^110
 ;;^UTILITY(U,$J,358.4,1049,0)
 ;;=OVERWEIGHT/OBESITY^4^110
 ;;^UTILITY(U,$J,358.4,1050,0)
 ;;=BODY MASS INDEX (BMI)^1^110
 ;;^UTILITY(U,$J,358.4,1051,0)
 ;;=NEW PATIENT^2^111
 ;;^UTILITY(U,$J,358.4,1052,0)
 ;;=ESTABLISHED PATIENT^1^111
 ;;^UTILITY(U,$J,358.4,1053,0)
 ;;=CONSULTATIONS^3^111
 ;;^UTILITY(U,$J,358.4,1054,0)
 ;;=ESTABLISHED PATIENT^2^112
 ;;^UTILITY(U,$J,358.4,1055,0)
 ;;=INJECTIONS/MEDICATION^10^113
 ;;^UTILITY(U,$J,358.4,1056,0)
 ;;=OTHER^11^113
 ;;^UTILITY(U,$J,358.4,1057,0)
 ;;=ALLERGY INJECTION^1^113
 ;;^UTILITY(U,$J,358.4,1058,0)
 ;;=INJECTION ADMINISTRATION^9^113
 ;;^UTILITY(U,$J,358.4,1059,0)
 ;;=IMMUNIZATION ADMINISTRATION ^6^113
 ;;^UTILITY(U,$J,358.4,1060,0)
 ;;=CATHETER^2^113
 ;;^UTILITY(U,$J,358.4,1061,0)
 ;;=CATH FLUSHES^3^113
 ;;^UTILITY(U,$J,358.4,1062,0)
 ;;=PFT^12^113
 ;;^UTILITY(U,$J,358.4,1063,0)
 ;;=EKG/HOLTER MONITOR^5^113
 ;;^UTILITY(U,$J,358.4,1064,0)
 ;;=IMMUNIZATIONS^7^113
 ;;^UTILITY(U,$J,358.4,1065,0)
 ;;=INFUSIONS^8^113
 ;;^UTILITY(U,$J,358.4,1066,0)
 ;;=PICC^13^113
 ;;^UTILITY(U,$J,358.4,1067,0)
 ;;=SMOKING CESSATION^14^113
 ;;^UTILITY(U,$J,358.4,1068,0)
 ;;=CHEMO AND OTH COMPLEX DRUGS^4^113
 ;;^UTILITY(U,$J,358.4,1069,0)
 ;;=SIGNS AND SYMPTOMS^1^114
 ;;^UTILITY(U,$J,358.4,1070,0)
 ;;=CARDIO/VASCULAR^2^114
 ;;^UTILITY(U,$J,358.4,1071,0)
 ;;=ENDOCRINE, METOBOLIC, NUTRITIONAL^4^114
 ;;^UTILITY(U,$J,358.4,1072,0)
 ;;=EYES, EARS, & NOSE^5^114
 ;;^UTILITY(U,$J,358.4,1073,0)
 ;;=GASTROINTESTINAL^6^114
 ;;^UTILITY(U,$J,358.4,1074,0)
 ;;=GENITOURINARY & RENAL^7^114
 ;;^UTILITY(U,$J,358.4,1075,0)
 ;;=MUSCULOSKETAL^9^114
 ;;^UTILITY(U,$J,358.4,1076,0)
 ;;=NEUROLOGY^10^114
 ;;^UTILITY(U,$J,358.4,1077,0)
 ;;=PULMONARY/RESPIRATORY^14^114
 ;;^UTILITY(U,$J,358.4,1078,0)
 ;;=PSYCHIATRIC^15^114
 ;;^UTILITY(U,$J,358.4,1079,0)
 ;;=SKIN^16^114
 ;;^UTILITY(U,$J,358.4,1080,0)
 ;;=IMMUNIZATIONS^8^114
 ;;^UTILITY(U,$J,358.4,1081,0)
 ;;=OTHER^12^114
 ;;^UTILITY(U,$J,358.4,1082,0)
 ;;=PREVENTIVE MEDICINE CODES^13^114
 ;;^UTILITY(U,$J,358.4,1083,0)
 ;;=NURSING MISCELLANEOUS^11^114
 ;;^UTILITY(U,$J,358.4,1084,0)
 ;;=COUNSELING^3^114
 ;;^UTILITY(U,$J,358.4,1085,0)
 ;;=CONTACT W/ HAZARDOUS SUBSTANCES^.5^114
 ;;^UTILITY(U,$J,358.4,1086,0)
 ;;=SPECIAL SERVICES^5^115
 ;;^UTILITY(U,$J,358.4,1087,0)
 ;;=TREATMENT^4^115
 ;;^UTILITY(U,$J,358.4,1088,0)
 ;;=MISCELLANEOUS^7^115
 ;;^UTILITY(U,$J,358.4,1089,0)
 ;;=IMMUNIZATIONS^6^115
 ;;^UTILITY(U,$J,358.4,1090,0)
 ;;=CHEMO ADMINISTRATION^1^115
 ;;^UTILITY(U,$J,358.4,1091,0)
 ;;=CHEMO DRUGS^2^115
 ;;^UTILITY(U,$J,358.4,1092,0)
 ;;=OTHER DRUGS^3^115
 ;;^UTILITY(U,$J,358.4,1093,0)
 ;;=NEW PATIENT^2^116
 ;;^UTILITY(U,$J,358.4,1094,0)
 ;;=ESTABLISHED PATIENT^1^116
 ;;^UTILITY(U,$J,358.4,1095,0)
 ;;=CONSULTATIONS^3^116
 ;;^UTILITY(U,$J,358.4,1096,0)
 ;;=ANEMIA^1^117
 ;;^UTILITY(U,$J,358.4,1097,0)
 ;;=COAGULATION DISORDERS^4^117
 ;;^UTILITY(U,$J,358.4,1098,0)
 ;;=MYELOID NEOPLASMS & DISORDERS^12^117
 ;;^UTILITY(U,$J,358.4,1099,0)
 ;;=LYMPHOID NEOPLASMS^9^117
 ;;^UTILITY(U,$J,358.4,1100,0)
 ;;=GI NEOPLASMS^7^117
 ;;^UTILITY(U,$J,358.4,1101,0)
 ;;=HEAD, NECK & LUNG NEOPLASMS^8^117
 ;;^UTILITY(U,$J,358.4,1102,0)
 ;;=MISC. NEOPLASMS^11^117
 ;;^UTILITY(U,$J,358.4,1103,0)
 ;;=METASTATIC SITES^10^117
 ;;^UTILITY(U,$J,358.4,1104,0)
 ;;=COUNSELING & SCREENING^5^117
 ;;^UTILITY(U,$J,358.4,1105,0)
 ;;=GENITOURINARY NEOPLASMS^6^117
 ;;^UTILITY(U,$J,358.4,1106,0)
 ;;=BREAST & GYN NEOPLASMS^3^117
 ;;^UTILITY(U,$J,358.4,1107,0)
 ;;=ARTIFICIAL OPENING STATUS^2^117
 ;;^UTILITY(U,$J,358.4,1108,0)
 ;;=PERSONAL HX OF CANCER^15^117
 ;;^UTILITY(U,$J,358.4,1109,0)
 ;;=NEOPLASMS OF UNCERTAIN BEHAVIOR^13^117
 ;;^UTILITY(U,$J,358.4,1110,0)
 ;;=NEOPLASMS OF UNSPECIFIED NATURE^14^117
 ;;^UTILITY(U,$J,358.4,1111,0)
 ;;=ESTABLISHED PATIENT^1^118
 ;;^UTILITY(U,$J,358.4,1112,0)
 ;;=CONSULTATION-CLINICIAN^2^118
 ;;^UTILITY(U,$J,358.4,1113,0)
 ;;=NEW PATIENT^3^118
 ;;^UTILITY(U,$J,358.4,1114,0)
 ;;=NEUROLYSIS^1^119
 ;;^UTILITY(U,$J,358.4,1115,0)
 ;;=NEUROSTIMULATORS^2^119
 ;;^UTILITY(U,$J,358.4,1116,0)
 ;;=OTHER PROCEDURES^3^119
 ;;^UTILITY(U,$J,358.4,1117,0)
 ;;=SPINAL PROCEDURES/NERVE BLOCKS^4^119
 ;;^UTILITY(U,$J,358.4,1118,0)
 ;;=SYMPTOMS^5^120
 ;;^UTILITY(U,$J,358.4,1119,0)
 ;;=ESTHESOPATHIES & ALLIED SYNDROMES^1^120
 ;;^UTILITY(U,$J,358.4,1120,0)
 ;;=HEADACHE^2^120
 ;;^UTILITY(U,$J,358.4,1121,0)
 ;;=SPINAL CONDITIONS^4^120
 ;;^UTILITY(U,$J,358.4,1122,0)
 ;;=PAIN^3^120
 ;;^UTILITY(U,$J,358.4,1123,0)
 ;;=INPT H&P-NEW ADMISSION^2^121
 ;;^UTILITY(U,$J,358.4,1124,0)
 ;;=INITIAL OBSERVATION^1^121
 ;;^UTILITY(U,$J,358.4,1125,0)
 ;;=INPT CONSULTATIONS^3^121
 ;;^UTILITY(U,$J,358.4,1126,0)
 ;;=INPT - ESTABLISHED PATIENT CARE^4^121
 ;;^UTILITY(U,$J,358.4,1127,0)
 ;;=INPATIENT DISCHARGES^5^121
 ;;^UTILITY(U,$J,358.4,1128,0)
 ;;=INJECTIONS/DRUGS^4^122
 ;;^UTILITY(U,$J,358.4,1129,0)
 ;;=WOUND CARE^12^122
 ;;^UTILITY(U,$J,358.4,1130,0)
 ;;=MD PROCEDURES^2^122
 ;;^UTILITY(U,$J,358.4,1131,0)
 ;;=MUSCLE NERVE TESTS^7^122
 ;;^UTILITY(U,$J,358.4,1132,0)
 ;;=TEAM CONFERENCE^9^122
 ;;^UTILITY(U,$J,358.4,1133,0)
 ;;=V CODES ^19^123
 ;;^UTILITY(U,$J,358.4,1134,0)
 ;;=AMPUTATION STATUS^3^123
 ;;^UTILITY(U,$J,358.4,1135,0)
 ;;=BRAIN DISORDERS^6^123
 ;;^UTILITY(U,$J,358.4,1136,0)
 ;;=CARDIOPULMONARY^7^123
 ;;^UTILITY(U,$J,358.4,1137,0)
 ;;=COMPLICATION DUE TO^9^123
 ;;^UTILITY(U,$J,358.4,1138,0)
 ;;=FRACTURES-LATE EFFECTS^11^123
 ;;^UTILITY(U,$J,358.4,1139,0)
 ;;=MENTAL DISORDERS^12^123
 ;;^UTILITY(U,$J,358.4,1140,0)
 ;;=MUSCULOSKELETAL/CONNECTIVE TISSUE^13^123
 ;;^UTILITY(U,$J,358.4,1141,0)
 ;;=LATE EFFECTS OF INJURY^1^123
 ;;^UTILITY(U,$J,358.4,1142,0)
 ;;=LATE EFFECTS OF CVA^2^123
 ;;^UTILITY(U,$J,358.4,1143,0)
 ;;=PHYSICAL CHANGES^15^123
 ;;^UTILITY(U,$J,358.4,1144,0)
 ;;=SPEECH AND LANGUAGE^18^123
 ;;^UTILITY(U,$J,358.4,1145,0)
 ;;=AUDITORY^4^123
 ;;^UTILITY(U,$J,358.4,1146,0)
 ;;=COGNITION^8^123
 ;;^UTILITY(U,$J,358.4,1147,0)
 ;;=PSYCHIATRIC-PSYCHOSOC-EMOTIONAL^17^123
 ;;^UTILITY(U,$J,358.4,1148,0)
 ;;=BACK DIAGNOSIS^5^123
 ;;^UTILITY(U,$J,358.4,1149,0)
 ;;=EXTREMITY DIAGNOSIS^10^123
 ;;^UTILITY(U,$J,358.4,1150,0)
 ;;=POST JOINT REPLACEMENT^16^123
 ;;^UTILITY(U,$J,358.4,1151,0)
 ;;=OTHER^14^123
 ;;^UTILITY(U,$J,358.4,1152,0)
 ;;=INITIAL EVAL FOR TBI^1^124
 ;;^UTILITY(U,$J,358.4,1153,0)
 ;;=EST PATIENT^1^125
 ;;^UTILITY(U,$J,358.4,1154,0)
 ;;=NEW PATIENT^2^125
 ;;^UTILITY(U,$J,358.4,1155,0)
 ;;=CONSULTATION^3^125
 ;;^UTILITY(U,$J,358.4,1156,0)
 ;;=INJECTIONS/DRUGS^4^126
 ;;^UTILITY(U,$J,358.4,1157,0)
 ;;=WOUND CARE^12^126
 ;;^UTILITY(U,$J,358.4,1158,0)
 ;;=MD PROCEDURES^2^126
 ;;^UTILITY(U,$J,358.4,1159,0)
 ;;=MUSCLE NERVE TESTS^7^126
 ;;^UTILITY(U,$J,358.4,1160,0)
 ;;=TEAM CONFERENCE^9^126
 ;;^UTILITY(U,$J,358.4,1161,0)
 ;;=OBSERVATION^1^126
 ;;^UTILITY(U,$J,358.4,1162,0)
 ;;=V CODES ^19^127
 ;;^UTILITY(U,$J,358.4,1163,0)
 ;;=AMPUTATION STATUS^3^127
 ;;^UTILITY(U,$J,358.4,1164,0)
 ;;=BRAIN DISORDERS^6^127
 ;;^UTILITY(U,$J,358.4,1165,0)
 ;;=CARDIOPULMONARY^7^127
 ;;^UTILITY(U,$J,358.4,1166,0)
 ;;=COMPLICATION DUE TO^9^127
 ;;^UTILITY(U,$J,358.4,1167,0)
 ;;=FRACTURES-LATE EFFECTS^11^127
 ;;^UTILITY(U,$J,358.4,1168,0)
 ;;=MENTAL DISORDERS^12^127
 ;;^UTILITY(U,$J,358.4,1169,0)
 ;;=MUSCULOSKELETAL/CONNECTIVE TISSUE^13^127
 ;;^UTILITY(U,$J,358.4,1170,0)
 ;;=LATE EFFECTS OF INJURY^1^127
 ;;^UTILITY(U,$J,358.4,1171,0)
 ;;=LATE EFFECTS OF CVA^2^127
 ;;^UTILITY(U,$J,358.4,1172,0)
 ;;=PHYSICAL CHANGES^15^127
 ;;^UTILITY(U,$J,358.4,1173,0)
 ;;=SPEECH AND LANGUAGE^18^127
